Critical Analysis: Rennova Health (OTCMKTS:RNVA) vs. MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH) and Rennova Health (OTCMKTS:RNVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for MDxHealth and Rennova Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	0	4	0	2.60
Rennova Health	0	0	0	0	0.00

MDxHealth currently has a consensus target price of $7.75, indicating a potential upside of 114.09%. Given MDxHealth’s stronger consensus rating and higher probable upside, equities research analysts clearly believe MDxHealth is more favorable than Rennova Health.

Risk and Volatility

MDxHealth has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Rennova Health has a beta of 22.39, meaning that its stock price is 2,139% more volatile than the S&P 500.

Profitability

This table compares MDxHealth and Rennova Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-30.50%	-1,078.01%	-20.05%
Rennova Health	N/A	N/A	N/A

Earnings and Valuation

This table compares MDxHealth and Rennova Health”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$90.05 million	1.90	-$38.07 million	($0.64)	-5.66
Rennova Health	$18.69 million	0.00	-$7.73 million	N/A	N/A

Rennova Health has lower revenue, but higher earnings than MDxHealth.

Summary

Rennova Health beats MDxHealth on 5 of the 9 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Rennova Health

Rennova Health, Inc., together with its subsidiaries, provides health care services in the United States. It owns one operating hospital in Oneida, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company is based in West Palm Beach, Florida.